文献速递脑血管病癫痫

预测脑静脉血栓形成后癫痫的临床评分:开发与验证

Development and Validation of a Clinical Score to Predict Epilepsy After Cerebral Venous Thrombosis.
PubMed 文献 · JAMA Neurol · 2024-01-01

这项观察性队列研究基于国际脑静脉血栓形成(CVT)联盟1128例患者开发DIAS3评分,并在ACTION-CVT(543例)和以色列CVT研究(556例)中外部验证。DIAS3评分由6个急性期临床变量构成,预测个体1年和3年癫痫风险范围分别为7%至68%和10%至83%,内部和外部验证的C统计量在0.74至0.80之间。该评分可帮助预测CVT后癫痫的个体风险。

要点

  • DIAS3评分基于6个急性期变量预测CVT后晚期癫痫风险。
  • 推导队列中11%患者在中位随访12个月发生CVT后癫痫。
  • 评分预测1年风险7%至68%,3年风险10%至83%,区分度良好。

核心结论

  • DIAS3评分(可在线免费获取)是一个简单工具,可帮助预测个体患者CVT后癫痫风险,可能有助于抗癫痫药物决策、患者咨询和CVT癫痫发生研究。

研究设计与样本

  • 观察性队列研究,纳入1994年至2022年回顾性和前瞻性患者。
  • 推导队列为国际CVT联盟(n=1128)的多中心队列;外部验证使用ACTION-CVT(n=543)和以色列CVT研究(n=556)两个独立多中心队列。
  • 共2937例连续入组的影像学确诊CVT成人患者中,排除CVT前有癫痫史、随访不足8天和晚期癫痫发作状态缺失者710例。

主要发现

  • 推导队列1128例患者(中位年龄41岁,IQR 30-53;女性805例,71%)中,128例(11%)在中位随访12个月(IQR 3-26)内发生CVT后癫痫。
  • DIAS3评分预测个体1年癫痫风险范围为7%至68%,3年风险范围为10%至83%。
  • 内部验证推导队列1年和3年C统计量均为0.74(95%CI 0.70-0.79)。
  • 外部验证ACTION-CVT队列1年C统计量0.76(95%CI 0.67-0.84),3年0.77(95%CI 0.66-0.84);以色列CVT研究1年C统计量0.80(95%CI 0.75-0.86)。
  • 校准图显示预测风险与观察风险一致性良好。

关键数值与推荐

  • DIAS3评分包含6个急性期可获取的临床变量:去骨瓣减压术、就诊时脑出血、年龄、急性期癫痫发作(不包括癫痫持续状态)、急性期癫痫持续状态、就诊时硬膜下血肿。
  • 晚期癫痫发作定义为CVT诊断后超过7天发生的首次癫痫发作。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: One of 10 patients develop epilepsy in the late phase after cerebral venous thrombosis (CVT) diagnosis but predicting the individual risk is difficult. OBJECTIVE: To develop and externally validate a prognostic score to estimate the individual risk of post-CVT epilepsy. DESIGN, SETTING, AND PARTICIPANTS: This observational cohort study included both retrospective and prospective patients enrolled from 1994 through 2022. For development of the DIAS3 score, data from the International CVT Consortium (n = 1128), a large international hospital-based multicenter CVT cohort, were used. For validation, data from 2 independent multicenter cohorts, the ACTION-CVT (n = 543) and the Israel CVT study (n = 556), were used. Of 2937 eligible, consecutively enrolled adult patients with radiologically verified CVT, 710 patients with a history of epilepsy prior to CVT, follow-up less than 8 days, and missing late seizure status were excluded. EXPOSURE: The prediction score (DIAS3) was developed based on available literature and clinical plausibility and consisted of 6 readily available clinical variables collected during the acute phase: decompressive hemicraniectomy, intracerebral hemorrhage at presentation, age, seizure(s) in the acute phase (excluding status epilepticus), status epilepticus in the acute phase, and subdural hematoma at presentation. MAIN OUTCOME AND MEASURE: Time to a first late seizure, defined as occurring more than 7 days after diagnosis of CVT. RESULTS: Of 1128 patients included in the derivation cohort (median age, 41 [IQR, 30-53] years; 805 women [71%]), 128 (11%) developed post-CVT epilepsy during a median follow-up of 12 (IQR, 3-26) months. According to the DIAS3 score, the predicted 1-year and 3-year risk of epilepsy in individual patients ranged from 7% to 68% and 10% to 83%, respectively. Internal and external validation showed adequate discrimination in the derivation cohort (1 year and 3 years: C statistic, 0.74; 95% CI, 0.70-0.79) and the 2 independent validation cohorts, (ACTION-CVT) 1 year: C statistic, 0.76; 95% CI, 0.67-0.84; 3 years: C statistic, 0.77; 95% CI, 0.66-0.84; and Israel CVT study 1 year: C statistic, 0.80; 95% CI, 0.75-0.86. Calibration plots indicated adequate agreement between predicted and observed risks. CONCLUSIONS AND RELEVANCE: The DIAS3 score (freely available online) is a simple tool that can help predict the risk of post-CVT epilepsy in individual patients. The model can improve opportunities for personalized medicine and may aid in decision-making regarding antiseizure medication, patient counseling, and facilitation of research on epileptogenesis in CVT.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Lindgren E, Shu L, Simaan N, et al. Development and Validation of a Clinical Score to Predict Epilepsy After Cerebral Venous Thrombosis. JAMA Neurol. 2024. PMID: 39432281. doi:10.1001/jamaneurol.2024.3481

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。